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The concept of a “local” renin angiotensin
system (RAS) can mean different things
to different people. Its main purpose is
to differentiate the “local” RAS operat-
ing in tissues from the classical “circu-
lating” RAS, but it is difficult to differ-
entiate between the two systems because
of their extensive overlap. The circulat-
ing RAS comprises kidney-derived renin
acting on liver-derived angiotensinogen to
generate angiotensin (Ang) I that is con-
verted to Ang II by angiotensin convert-
ing enzyme (ACE). However, tissues are
the main site of production of angiotensin
peptides by the circulating RAS, whereby
plasma-derived renin acts on plasma-
derived angiotensinogen to generate Ang I,
which is converted to Ang II by endothelial
ACE (1–4).
Local RAS refers to tissue-based mecha-
nisms of Ang peptide formation that oper-
ate separately from the circulating RAS.
Although many different concepts of local
RAS have been described, a key feature
is the local synthesis of RAS components
including angiotensinogen and enzymes
such as renin that cleave angiotensino-
gen to produce Ang peptides indepen-
dently of the circulating RAS. ACE and
Ang II type 1 (AT1) and type 2 (AT2)
receptors are invariably locally synthe-
sized, but these are also components of
the circulating RAS. Many other poten-
tial components of local RAS have been
described that may contribute to tissue-
specific mechanisms of Ang peptide for-
mation, and that may either partici-
pate in disease processes or contribute
to mechanisms that protect from tissue
injury. These include the (pro)renin recep-
tor (5), renin-independent mechanisms of
Ang peptide generation from Ang- (1-
12) (6), intracellular (or intracrine) RAS
that may contribute to cardiovascular dis-
ease (7, 8), and AT2 receptors (7) and
the ACE2/Ang-(1-7)/Mas receptor path-
way (6–8) that may mediate therapeutic
benefit in cardiovascular disease. In addi-
tion, novel Ang peptides with novel phar-
macology, including Ang IV, Ang A, ala-
mandine, and angioprotectin (6, 8), have
the potential to contribute to disease or
to protective mechanisms. Moreover, the
brain RAS, including the ACE2/Ang-(1-
7)/Mas receptor and the Ang IV/insulin
regulated aminopeptidase pathways may
play a role in Alzheimer’s and Parkinson’s
diseases (9). Local production of aldos-
terone may have a pathogenic role (7,
10), ACE, AT2 receptors, Ang-(1-7) and
acetyl-Ser-Asp-Lys-Pro may have a role in
hematopoiesis (11), and the ACE2/Ang-(1-
7)/Mas receptor pathway may contribute
to fetal programing, reproduction, and
cancer (6, 12).
This short opinion piece discusses the
potential clinical relevance of local RAS.
The challenge in demonstrating the inde-
pendence of local from circulating RAS,
and the potential interaction of ACE
inhibitor and AT1 receptor blocker (ARB)
therapies with local RAS are discussed.
Attempts to define local RAS that are
independent of the circulating RAS have
been primarily based on animal mod-
els and the clinical relevance of local
RAS is uncertain. However, this area of
research continues to evolve, and today’s
opinions may change as we gain better
understanding of how these novel compo-
nents and mechanisms impact on clinical
medicine.
HOW CAN LOCAL RAS BE SHOWN TO
BE INDEPENDENT OF THE
CIRCULATING RAS?
As reviewed elsewhere (5–12), many lines
of evidence suggest the possibility of local
RAS that may operate independently of
the circulating RAS and play a patho-
genic or protective role. This evidence
includes the widespread tissue expression
of angiotensinogen, the only known pre-
cursor of the Ang peptides and an essen-
tial requirement for an independent local
RAS (13–16). However, local production
of RAS components does not prove their
functional significance, and proving their
clinical relevance presents many challenges.
One approach to study of the role of
locally synthesized RAS components is
their targeted deletion from specific tis-
sues. This approach has been applied to the
kidney.
Both clinical experiences with ACE
inhibitor and ARB therapies during preg-
nancy, and ACE, renin, angiotensinogen,
and AT1 receptor gene mutation and
knockout models demonstrate a critical
role for the RAS in renal development and
function in animals and humans (17–23).
Moreover, ACE inhibition demonstrates a
differential regulation of Ang II levels in
kidney and blood (24). However, these data
do not prove a specific role for the local RAS
in the kidney. Matsusaka et al. investigated
the role of the local RAS in renal develop-
ment and function by producing mice with
genetic deletion of angiotensinogen syn-
thesis in the kidney. In contrast to the mor-
phological and functional consequences
of whole body or liver specific deletion
of angiotensinogen gene expression, dele-
tion of angiotensinogen production in the
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kidney had no effect on renal morphol-
ogy or function (25). Moreover, contrary
to the expectation that locally produced
angiotensinogen was the main contribu-
tor to renal Ang II levels, Matsusaka et al.
showed deletion of renal angiotensinogen
production had no effect on renal Ang II
levels, and that liver angiotensinogen is
the primary source of Ang II in the kid-
ney (25). With the caveat that the studies
of Matsusaka et al. were not in patho-
physiological models (25), these data show
that evidence for local synthesis of a RAS
component is not sufficient to establish
a role for the locally synthesized compo-
nent in physiology or pathology, whether
by an intracellular (intracrine) or extra-
cellular mechanism. Proof that a locally
synthesized RAS component contributes to
physiology or pathology requires demon-
stration that deletion of the locally syn-
thesized component impacts on physiology
and/or pathology.
Similar to the case for angiotensino-
gen, mice with reduced renal expression
of ACE had normal histology and urine
concentrating ability (26), suggesting that
locally synthesized ACE does not play an
essential role in normal renal development
and function. Moreover, the marked reduc-
tion in Ang II levels in kidney, heart, and
other organs caused by global ACE gene
deletion, despite near-normal Ang I lev-
els (27, 28), indicates that an intracellular
(intracrine) ACE-independent mechanism
of Ang II formation is unlikely to exist in
these tissues.
Evidence for a pathogenic role of renal
ACE is the demonstration that genetic dele-
tion of renal ACE expression prevented
hypertension produced by subcutaneous
administration of Ang II (26), suggesting a
specific renal ACE-dependent mechanism
of hypertension in this model. However,
the significance of this finding is uncer-
tain because ACE inhibition does not mod-
ify hypertension produced by intravenous
Ang II administration in either animal of
human studies (29–33), and it is ques-
tionable whether the subcutaneous Ang II
model of hypertension has any physiologi-
cal or pathological relevance (34).
An alternative approach to defining a
local tissue RAS was to use recombinant
technology to express ACE as a reporter
gene on the cardiomyocyte membrane
(35). In this model, ACE expression on the
cardiomyocyte membrane (where it is not
normally expressed) would be expected to
increase cardiac Ang II levels if Ang I were
also present in this tissue compartment.
Expression of ACE on the cardiomyocyte
membrane increased cardiac Ang II levels
in mice without endothelial expression of
ACE, but not in rats or mice with endothe-
lial ACE expression (35, 36). These studies
do not therefore provide evidence in sup-
port of Ang I formation in the extravascu-
lar compartment of the heart of animals
with endothelial ACE expression. By con-
trast, deletion of testicular ACE reduced
male fertility (37), indicating a specific
role for testicular ACE. However, ACE has
many substrates (38) and the reduction in
male fertility may reflect an action of tes-
ticular ACE that is independent of Ang
peptides.
Part of the challenge in identifying a
local RAS that is independent of the cir-
culating RAS is the difficulty in measur-
ing in vivo levels of Ang peptides in tis-
sues. For example, initial reports of sub-
stantial amounts of Ang II and Ang-(1-
7) in the brain (39, 40) were not con-
firmed when more rigorous methodology
was applied (41, 42).
DO THE THERAPEUTIC BENEFITS OF
ACE INHIBITOR AND ARB THERAPIES
ESTABLISH THE CLINICAL RELEVANCE
OF LOCAL RAS?
A key argument in support of the clin-
ical relevance of the RAS, whether local
or circulating, is the therapeutic benefit
from inhibition of this system. De Mello
and Frohlich proposed that the local RAS
mediates in part the therapeutic benefits of
ACE inhibitor and ARB therapies (7), but
there are difficulties in establishing such a
role for local RAS. For example, the claim
that the beneficial effects of these therapies
occurred independently of blood pressure
(7) suggests, but does not prove, a role
for local RAS. The complexity of blood
pressure regulation means that alternative
explanations are possible and ambulatory
blood pressure monitoring may be neces-
sary to demonstrate an effect of therapy on
blood pressure not detected by office blood
pressure measurement (43). Furthermore,
the different benefits of ACE inhibitor and
ARB therapies in comparison with antihy-
pertensive agents that act independently of
the RAS (7) do not prove that these benefits
were due to inhibition of local rather than
the circulating RAS.
Ang II administration is a well-
recognized model of cardiovascular and
renal disease (44–46), and the therapeu-
tic benefits of RAS inhibition are almost
certainly in large part a consequence of
reduced Ang II stimulation of the AT1
receptor in high renin, high Ang II condi-
tions such as renal artery stenosis and heart
failure. Reduced AT1 receptor stimulation
may also play an important role in the renal
effects of RAS inhibition, including the side
effects of these therapies (47, 48). Many
studies investigating the combination of
ACE inhibitor, ARB, and renin inhibitor
therapies were based on the assumption
that the therapeutic benefits of these agents
are the consequence of reduced AT1 recep-
tor stimulation, and that combination of
these therapies would produce greater ther-
apeutic benefit by producing greater reduc-
tion in AT1 receptor stimulation (47–53).
What may not have been appreciated was
the large body of preclinical and clinical
data indicating that these drugs also pro-
duce benefits by mechanisms separate from
reduced AT1 receptor stimulation. More-
over, many of these mechanisms separate
from reduced AT1 receptor stimulation
involve novel RAS components implicated
in local tissue RAS (Figure 1). For exam-
ple,ARB therapies, by blocking the negative
feedback control of renin secretion, also
increase Ang II levels that stimulate the
AT2 receptor, leading to cardioprotection
(54, 55). Moreover, both ACE inhibitor and
ARB therapies increased Ang-(1-7) levels
(56) that may produce therapeutic effects
mediated by the Ang-(1-7)/Mas receptor
pathway (6). In addition, ACE inhibitor,
ARB, and renin inhibitor therapies increase
bradykinin levels that may contribute to
their antihypertensive and cardioprotec-
tive actions (54, 55, 57–63). Consequently,
therapeutic benefit from ACE inhibitor,
ARB, and renin inhibitor therapies does not
prove a pathogenic role for the RAS, either
local or circulating.
An important aspect of these additional
mechanisms of therapeutic benefit from
RAS inhibition is that combination of ACE
inhibitor, ARB, and/or renin inhibitor ther-
apies may block some of these mechanisms
of benefit, thereby explaining the many
clinical studies, apart from heart failure
(49), that showed no additional benefit
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FIGURE 1 | Diagrammatic representation of angiotensin (Ang) and bradykinin peptide formation
and metabolism, with the sites of action of angiotensin converting enzyme (ACE) inhibitors
(ACEI), angiotensin type 1 (AT1) receptor blockers (ARB), and the renin inhibitor aliskiren. In
addition to inhibiting renin, aliskiren increases tissue kallikrein activity and bradykinin levels that may act
on bradykinin type 1 (B1) and type 2 (B2) receptors (55). Neutral endopeptidase (NEP) converts Ang I to
Ang-(1-7), ACE2 converts Ang II to Ang-(1-7), and aminopeptidases convert Ang II to Ang III and Ang IV.
from combination of ACE inhibitor, ARB,
and renin inhibitor therapies (47, 48, 50–
53). For example, the benefits of ARB ther-
apy produced by increased Ang II levels and
AT2 receptor stimulation will be blocked
if combined with renin inhibitor or ACE
inhibitor therapies, because renin inhibitor
and ACE inhibitor therapies attenuate the
increase in Ang II levels produced by ARB
therapy (55, 56, 64, 65). Moreover, the
benefits of ACE inhibitor and ARB thera-
pies produced by increased Ang-(1-7) lev-
els and Mas receptor stimulation will be
blocked if combined with renin inhibitor
or neutral endopeptidase inhibitor thera-
pies because renin inhibitor and neutral
endopeptidase inhibitor therapies attenu-
ate the increase in Ang-(1-7) levels pro-
duced by ACE inhibitor and ARB therapies
(66). In addition, neutral endopeptidase
inhibitor therapy may increase Ang II levels
by reducing Ang II metabolism (66, 67).
CONCLUSION
Current concepts of the local RAS have
expanded to include the (pro)renin recep-
tor, renin-independent mechanisms of
Ang peptide generation from Ang-(1-12),
AT2 receptors, the ACE2/Ang-(1-7)/Mas
receptor and Ang IV/insulin regulated
aminopeptidase pathways, an intracellu-
lar (intracrine) RAS, and novel Ang pep-
tides (5–9, 11, 12). Much of the evidence
for these new RAS components is based
on animal studies and further research is
required to establish that local RAS con-
tribute to physiology and disease. Con-
sequently, the clinical relevance of local
RAS remains speculative. Nevertheless, the
expanding repertoire of local RAS compo-
nents offers new therapeutic targets and the
prospect of new therapies.
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